## IN THE UNITED STATES PATENT AND TRADE K OFFICE REQUEST OR FILING NATIONAL PATENT AFTER LICATION

Under 35 USC 111(a) and Rule 53(b)

PATENT APPLICATION

Hon. Commissioner of Patents Washington, D.C. 20231



Sir:

WITH <u>UNSIGNED</u>
DECLARATION
NONPROVISIONAL
NON REISSUE
NON PCT NAT PHASE



Herewith is the  $\underline{\mathsf{PATENT}}\ \mathsf{APPLICATION}$  of

Inventor(s): Nabil Hanna and Kandasamy Hariharan

Title		nancies Using Combination of B of the Modulating Antibody Related	ted	P 0276658	Client Ref	
including:			Date: January 31, 2001			
Specification: 55 pages (only spec. and claims) 2. Specification in non-English language  Declaration Original Unsigned Copy Abstract 1 page(s); 18 numbered claims  Drawings: 6 sheet(s) informal; Sommal of size: A4 11"  See top first page re prior Provisional, National or International application(s). ("X" box only if info is there and do not complete corresponding item 5 or 6). (Prior M# 0275478 SN 09/435,992 )  AMEND the specification please by inserting before the first line: This is a Continuation-in-Part Divisional Continuation Substitute Application (MPEP 201.09) of:  G(a) National Appln. No. / filed (M# )  Substitute Application (MPEP 201.09) of:  G(b) International Appln. No. / filed (M# )  AMEND the specification by inserting before the first line: This application claims the benefit of U.S.  Provisional Application No. 60/ , filed  ALEND Attached is an assignment and cover sheet. Please return the recorded assignment to the undersigned.						
	9. Prior application is assigned to IDEC Pharmaceuticals Corporation  San Diego, California U.S.A.					
	by Assignment recorde	d January 10, 2000 R	eel 010480	Fra	ame _0433	
10. <u>FC</u>	<b>DREIGN</b> priority is claimed	l under 35 USC 119(a)-(d)/365(b)	based on filing in			
11				(country)		
A	pplication No.	Filing Date	Application No.	Filing	Date	
	1)		(2)			
<u>  (</u>	3)		(4)			
<u>(</u> :	5)		(6)			
	7)	·	(3)			
(9	(9) See 3 <sup>rd</sup> page for additional priorties					
12.	12 (No.) Certified copy (copies):					
	in U.S. Application No. / filed on					

is not claimed;

is claimed (Pre-filing confirmation required)

(No.) Small Entity Statement(s) (since 9/8/00 small entity statement(s) not essential to make claim)

13(a). Attached:

13.

Small entity status Ø

14. <u>DOMESTIC/INTERNATIONAL</u> priority is claimed under 35 USC 119(e)/120/365(c) based on the following provisional, nonprovisional and/or PCT international application(s):

Application No.	Filing Date	Application No.	Filing Date	
(1) 09/435,992	8 November 1999	(4)		
(2)		(5)		
(3)		(6)		

15. This application is being filed under Rule 53(b)(2) since an inventor is named in the enclosed Declaration who was not named in the prior application.  16. Attached:
17. Preliminary Amendment:

## THE FOLLOWING FILING FEE IS BASED ON CLAIMS AS FILED LESS ANY ABOVE CANCELLED

A.C				Large/Small Entity		Fee
달 - 1호 L						Code
18. Basic Filing Fee				\$710/\$355	\$710	101/201
19. Total Effective Claims	18	minus 20 =	*0	x \$18/\$9 =	+0	103/203
20. Independent Claims	1	minus 3 =	*0	x \$80/\$40 =	+0	102/202
				*If answer is zero or less, enter *0*		
21. If any proper multiple dependent claim (ignore improper) is present, add				+ \$270/\$135	+0	104/204
Leave this line blank if this i	s a reissue a	ipplication)				
22.			TOTAL FI	LING FEE ENCLOSED =	\$710	
23. If "non-English" box 2 is X'd, add Rule 17(k) processing fee				+ \$130	+0	139
24. If "assignment" box 8 is X'd, add recording fee				+ \$40	+0	581
25. Attached is a Petition/Fee under Rule No.				+ \$130	+0	122
26. TOTAL FEE TO BE CHARGED TO DEPOSIT				\$710		

CHARGE to De	posit Account No. 03	3-3975	<u></u>	
Our Order No.	037003	0276658	<b>'</b>	
	C#	M#		00909

CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached.

This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.

Pillsbury Winthrop LLP Intellectual Property Group

	By Atty: Robin L. Teskin	Reg. No35,030
	Sig: Ru. Ilm	Fax: (202) 822-0944
Atty/Sec: RLT/kmh		Tel: (202) 861-3623
IOTE: File in dunlingte with	2 most gard receipts (DAT 103) & attachments	